Stability-Indicating LC Determination of a New Antihypertensive, Olmesartan Medoxomil in Tablets

被引:17
作者
Bajerski, Lisiane [1 ]
Rossi, Rochele C. [1 ]
Dias, Carolina L. [1 ]
Bergold, Ana M. [1 ]
Froehlich, Pedro E. [1 ]
机构
[1] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Farmaceut, Fac Farm, BR-90610000 Porto Alegre, RS, Brazil
关键词
Column liquid chromatography; Stability-indicating method; Forced degradation; Validation; Olmesartan medoxomil;
D O I
10.1365/s10337-008-0811-3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A stability-indicating liquid chromatographic method was developed and validated for quantitative determination of olmesartan medoxomil (OLM) in coated tablets in the presence of degradation products generated under stress conditions. An isocratic LC separation was performed using a Phenomenex RP-18 column using a mobile phase consisting of water: triethylamine: acetonitrile (60:0.3:40 v/v/v, pH adjusted to 6.3 with phosphoric acid). The flow rate was 1.2 mL min(-1) and the detection was achieved with a photodiode array detector set at 257 nm. The response was linear over a range of 10.0 to 30.0 mu g mL(-1) (r = 0.9999). The specificity and stability-indicating capability of the method was verified subjecting the reference substance and drug product to hydrolytic, oxidative, photolytic, and thermal stress conditions. The method showed a good and consistent recovery (100.2%) with low intra- and inter-day relative standard deviation (RSD) (<= 1.0%). A considerable degradation occurred in all stress conditions and the degradation product was well resolved from the main peak. There was no interference of the excipients in the determination of the active pharmaceutical ingredient. Thus, the proposed method was found to be stability-indicating and can be used for routine analysis for quantitative determination of OLM in coated tablets without the interference of major degradation products.
引用
收藏
页码:991 / 996
页数:6
相关论文
共 15 条
[1]   Determination of olmesartan medoxomil in tablets by UV-Vis spectrophotometry [J].
Celebier, M. ;
Altinoz, S. .
PHARMAZIE, 2007, 62 (06) :419-422
[2]   Development of a CZE method for the determination of Olmesartan medoxomil in tablets [J].
Celebier, Mustafa ;
Altinoez, Sacide .
CHROMATOGRAPHIA, 2007, 66 (11-12) :929-933
[3]  
Food and Drug Administration, 1994, CTR DRUG EV RES REV
[4]  
*ICH, 2005, HARM TRIP GUID VAL A
[5]  
*ICH, 1996, HARM TRIP GUID VAL
[6]  
ICH Harmonized Tripartite Guideline, 2003, HARM TRIP GUID STAB
[7]  
Laeis Petra, 2001, Journal of Hypertension, V19, pS21
[8]  
Lui D., 2007, J CHROMATOGR B, V856, P190, DOI DOI 10.1016/J.JCHROMB.2007.05.049
[9]   Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC hyphenated techniques [J].
Murakami, Tomonori ;
Konno, Hidetoshi ;
Fukutsu, Naoto ;
Onodera, Michinobu ;
Kawasaki, Takao ;
Kusu, Fumiyo .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 47 (03) :553-559
[10]   Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models [J].
Nakamura, H ;
Inoue, T ;
Arakawa, N ;
Shimizu, Y ;
Yoshigae, Y ;
Fujimori, I ;
Shimakawa, E ;
Toyoshi, T ;
Yokoyama, T .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 512 (2-3) :239-246